Singapore-based Nanyang Biologics announced a $1.5 billion business combination agreement with Nasdaq-listed RF Acquisition Corp II to go public. NYB is building a hybrid drug discovery platform integrating machine learning with extensive natural compound libraries, claiming one of the world’s largest AI-curated bioactive compound collections. The company aims to revolutionize drug R&D by accelerating discovery while reducing costs, reflecting growing trends towards AI-powered precision medicine in the industry.